- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Orthopedic Research Online Journal
Effects of the First Decade of Osteoporosis - Therapy with Denosumab (DMAB)
-
Open or Close Tassilo König*
Practice for Orthopaedics / Osteological Specialist Centre DVO, Germany
*Corresponding author: Tassilo König, Practice for Orthopaedics / Osteological Specialist Centre DVO, Germany
Submission: February 20, 2020;Published: February 27, 2020
ISSN : 2576-8875Volume6 Issue5
Abstract
After 10 years of therapy of osteoporosis with the monoclonal antibody Denosumab
(Prolia°) we look back on the results. Can new fractures be prevented under Denosumab?
How long do patients stay on therapy?
The primary goal of osteoporosis therapy is to avoid fractures. Especially major fractures
such as radius, femoral neck and vertebral body fractures are accompanied by functional
losses, sometimes severe pain and reduced quality of life. Those affected with vertebral body
fractures report the most severe pain, often requiring opioid therapy. Fractured osteoporosis
patients have an increased risk of death.
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version